DeGette Statement Following OMB Attempt to Slash NIH, Biomedical Research

DENVER, CO — Today, Congresswoman Diana DeGette (CO-01), Ranking Member of the Energy and Commerce Subcommittee on Health, issued the following statement after the Office of Management and Budget (OMB) reversed course on directing the National Institutes of Health (NIH) to only use appropriated dollars for salaries, administrative expenses, and expenses associated with the NIH Clinical Center which would have prohibited the investment of at least $15 billion in biomedical research.

“The Office of Management and Budget may not change or disregard the law. Congress appropriated $47.3 billion for NIH in fiscal year 2024 appropriations, and it continued that funding level in the fiscal year 2025 continuing resolution. That funding was made available to support research, not just at NIH but at institutions across the country and around the world. OMB and its director, Russ Vought, may not change that reality with the stroke of a pen.

“NIH-funded research has fueled treatments and cures for sickle cell disease, Hepatitis C, and cystic fibrosis. It has led to effective treatments for myriad cancers, leading in part to a reduction in the cancer death rate by a third in the past 30 years. Halting this progress means death and misery for millions of Americans with diseases that NIH seeks to cure. That is why Congress has continued to empower NIH. Congress has given OMB and NIH zero authority to curtail grantmaking.

“Russ Vought’s latest attempt to strangle biomedical research is just a continuation of his disdain for Congress, science, and the American people. It was apparently a bridge too far, even for Donald Trump and the White House, which reportedly pushed back on the directive from OMB and Vought. There must be accountability for this directive, and Director Vought must testify before Congress to explain his illegal attempt to gut biomedical research.” 

###